EpiCept’s vision is to create and develop products that make a meaningful difference in people’s lives. As such, it is dedicated to successfully and continually improving the quality of life of pain sufferers and increasing the life span of cancer patients.

Our mission is the relentless pursuit of satisfying unmet medical needs with pharmacologic agents that are based on sound scientific findings, demonstrated safety and efficacy, and unique and proven technologies. We are focused on advancing a pipeline of world-class products that treat moderate-to-severe pain and malignant diseases.

In the area of cancer, EpiCept is continuing to advance Ceplene™ for the treatment of Acute Myeloid Leukemia (AML) as remission maintenance therapy. Ceplene is currently undergoing a Marketing Authorization Application (MAA) review by the European Medicines Agency (EMEA). The Company also possesses a proprietary drug discovery platform that allows it to uncover new compounds in the treatment of cancer and two drug candidates in clinical trials from this platform.

In the area of pain, EpiCept’s product candidates are designed to topically deliver FDA-approved pain management therapeutics directly to the surface of the skin, which the Company believes will offer patients a safer, more beneficial form of pain relief than traditional systemic forms of analgesics. Because these product candidates utilize FDA-approved drug substances, EpiCept believes that there will be a more streamlined regulatory approval pathway for these product candidates, reducing development risk and costs and potentially accelerating the time to market.

EpiCept seeks to generate significant value for its shareholders by developing effective drug candidates, including new chemical entities and new uses for existing therapies, advancing them into late-stage clinical development and then seeking marketing approval either alone or in conjunction with strategic partners.